Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.15
SLXP's Cash to Debt is ranked lower than
52% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. SLXP: 0.15 )
SLXP' s 10-Year Cash to Debt Range
Min: 0.14   Max: No Debt
Current: 0.15

Equity to Asset 0.11
SLXP's Equity to Asset is ranked lower than
54% of the 822 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. SLXP: 0.11 )
SLXP' s 10-Year Equity to Asset Range
Min: 0.11   Max: 0.9
Current: 0.11

0.11
0.9
Interest Coverage 4.41
SLXP's Interest Coverage is ranked higher than
52% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 120.76 vs. SLXP: 4.41 )
SLXP' s 10-Year Interest Coverage Range
Min: 3.1   Max: 9999.99
Current: 4.41

3.1
9999.99
F-Score: 5
Z-Score: 1.30
M-Score: -1.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 1.94
SLXP's Operating margin (%) is ranked higher than
63% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. SLXP: 1.94 )
SLXP' s 10-Year Operating margin (%) Range
Min: -511.93   Max: 29.1
Current: 1.94

-511.93
29.1
Net-margin (%) -5.58
SLXP's Net-margin (%) is ranked higher than
56% of the 860 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. SLXP: -5.58 )
SLXP' s 10-Year Net-margin (%) Range
Min: -475.24   Max: 16.17
Current: -5.58

-475.24
16.17
ROE (%) -11.33
SLXP's ROE (%) is ranked higher than
57% of the 879 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.98 vs. SLXP: -11.33 )
SLXP' s 10-Year ROE (%) Range
Min: -102   Max: 21.98
Current: -11.33

-102
21.98
ROA (%) -1.98
SLXP's ROA (%) is ranked higher than
60% of the 913 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.21 vs. SLXP: -1.98 )
SLXP' s 10-Year ROA (%) Range
Min: -77.4   Max: 10.41
Current: -1.98

-77.4
10.41
ROC (Joel Greenblatt) (%) 5.47
SLXP's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.70 vs. SLXP: 5.47 )
SLXP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7190.09   Max: 161.23
Current: 5.47

-7190.09
161.23
Revenue Growth (3Y)(%) 34.20
SLXP's Revenue Growth (3Y)(%) is ranked higher than
93% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. SLXP: 34.20 )
SLXP' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2   Max: 112.5
Current: 34.2

-2
112.5
EBITDA Growth (3Y)(%) 207.90
SLXP's EBITDA Growth (3Y)(%) is ranked higher than
100% of the 702 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.30 vs. SLXP: 207.90 )
SLXP' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -28.2   Max: 207.9
Current: 207.9

-28.2
207.9
» SLXP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

SLXP Guru Trades in Q4 2013

Jim Simons 268,519 sh (+2.45%)
Vanguard Health Care Fund 2,147,945 sh (unchged)
Pioneer Investments 410,439 sh (-9.38%)
Steven Cohen 97,861 sh (-57.52%)
Paul Tudor Jones 3,200 sh (-61.9%)
» More
Q1 2014

SLXP Guru Trades in Q1 2014

Andreas Halvorsen 1,551,766 sh (New)
Joel Greenblatt 307,445 sh (New)
Paul Tudor Jones 7,400 sh (+131.25%)
Pioneer Investments 450,432 sh (+9.74%)
Vanguard Health Care Fund 2,032,845 sh (-5.36%)
Jim Simons 90,134 sh (-66.43%)
Steven Cohen 7,830 sh (-92%)
» More
Q2 2014

SLXP Guru Trades in Q2 2014

Jim Simons 257,819 sh (+186.04%)
Andreas Halvorsen 2,889,303 sh (+86.19%)
Steven Cohen 527,800 sh (unchged)
Joel Greenblatt Sold Out
Pioneer Investments 417,255 sh (-7.37%)
Vanguard Health Care Fund 1,824,545 sh (-10.25%)
Paul Tudor Jones 1,800 sh (-75.68%)
» More
Q3 2014

SLXP Guru Trades in Q3 2014

Paul Tudor Jones 12,629 sh (+601.61%)
Andreas Halvorsen 2,719,538 sh (-5.88%)
Vanguard Health Care Fund 1,538,045 sh (-15.7%)
Pioneer Investments 306,515 sh (-26.54%)
Steven Cohen 150,000 sh (-71.58%)
Jim Simons 44,525 sh (-82.73%)
» More
» Details

Insider Trades

Latest Guru Trades with SLXP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Andreas Halvorsen 2014-06-30 Add 86.19%0.74%$97.7 - $125.07 $ 117.26%2889303
Joel Greenblatt 2014-06-30 Sold Out 0.48%$97.7 - $125.07 $ 117.26%0
Andreas Halvorsen 2014-03-31 New Buy0.67%$88.8 - $114.64 $ 117.215%1551766
Joel Greenblatt 2014-03-31 New Buy0.48%$88.8 - $114.64 $ 117.215%307445
Joel Greenblatt 2013-09-30 Sold Out 0.36%$65.73 - $75.54 $ 117.270%0
Joel Greenblatt 2013-06-30 New Buy0.36%$47.72 - $66.83 $ 117.2105%127495
Joel Greenblatt 2013-03-31 Sold Out 0.15%$40.472 - $51.37 $ 117.2144%0
Vanguard Health Care Fund 2013-03-31 Add 22.44%0.08%$40.472 - $51.37 $ 117.2144%2147945
NWQ Managers 2012-12-31 Sold Out 0.17%$37.97 - $42.9 $ 117.2187%0
Joel Greenblatt 2012-12-31 Add 75.81%0.06%$37.97 - $42.9 $ 117.2187%63399
Joel Greenblatt 2012-09-30 New Buy0.1%$41.92 - $55.65 $ 117.2147%36061
NWQ Managers 2012-03-31 Reduce -40.33%0.14%$45.72 - $53.75 $ 117.2154%656533
John Paulson 2011-09-30 Sold Out 0.2056%$26.18 - $40.9 $ 117.2254%0
NWQ Managers 2011-09-30 Add 198.07%0.18%$26.18 - $40.9 $ 117.2254%1320679
Vanguard Health Care Fund 2011-09-30 Add 55.43%0.09%$26.18 - $40.9 $ 117.2254%1554300
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 14.14
SLXP's P/B is ranked higher than
52% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. SLXP: 14.14 )
SLXP' s 10-Year P/B Range
Min: 1.01   Max: 19.81
Current: 14.14

1.01
19.81
P/S 5.49
SLXP's P/S is ranked higher than
67% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. SLXP: 5.49 )
SLXP' s 10-Year P/S Range
Min: 1.28   Max: 12.23
Current: 5.49

1.28
12.23
PFCF 49.24
SLXP's PFCF is ranked higher than
86% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. SLXP: 49.24 )
SLXP' s 10-Year PFCF Range
Min: 5.08   Max: 371
Current: 49.24

5.08
371
EV-to-EBIT 369.14
SLXP's EV-to-EBIT is ranked higher than
64% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.43 vs. SLXP: 369.14 )
SLXP' s 10-Year EV-to-EBIT Range
Min: -1044.1   Max: 481.4
Current: 369.14

-1044.1
481.4
Shiller P/E 808.27
SLXP's Shiller P/E is ranked higher than
73% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.36 vs. SLXP: 808.27 )
SLXP' s 10-Year Shiller P/E Range
Min: 240.14   Max: 4937
Current: 808.27

240.14
4937
Current Ratio 0.94
SLXP's Current Ratio is ranked lower than
52% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. SLXP: 0.94 )
SLXP' s 10-Year Current Ratio Range
Min: 0.94   Max: 8.65
Current: 0.94

0.94
8.65
Quick Ratio 0.84
SLXP's Quick Ratio is ranked higher than
51% of the 891 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. SLXP: 0.84 )
SLXP' s 10-Year Quick Ratio Range
Min: 0.84   Max: 7.92
Current: 0.84

0.84
7.92

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 5.54
SLXP's Price/DCF (Projected) is ranked higher than
79% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.90 vs. SLXP: 5.54 )
SLXP' s 10-Year Price/DCF (Projected) Range
Min: 2.38   Max: 76.06
Current: 5.54

2.38
76.06
Price/Median PS Value 1.14
SLXP's Price/Median PS Value is ranked higher than
82% of the 947 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. SLXP: 1.14 )
SLXP' s 10-Year Price/Median PS Value Range
Min: 0.29   Max: 3.89
Current: 1.14

0.29
3.89
Earnings Yield (Greenblatt) 0.30
SLXP's Earnings Yield (Greenblatt) is ranked higher than
63% of the 906 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. SLXP: 0.30 )
SLXP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 9.7
Current: 0.3

0.2
9.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:XP2.Germany,
Salix Pharmaceuticals Ltd is a Delaware corporation incorporated on December 1993. The Company is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal diseases, which are those affecting the digestive tract. The Companys search and development efforts are designed to identify and acquire late-stage and/or marketed proprietary pharmaceutical products for the treatment of gastrointestinal disease that have an existing base of safety and efficacy data. Its products include APRISO, the first and only mesalamine product approved by the FDA for once-a-day dosing for the maintenance of remission of ulcerative colitis. Another product, COLAZAL, treats mildly to moderately active ulcerative colitis, a form of inflammatory bowel disease. XIFAXAN is a nonsystemic antibiotic that treats travelers' diarrhea caused by noninvasive E. coli. PEPCID treats active duodenal ulcer, active benign gastric ulcer, and gastroesophageal reflux disease (GERD). OsmoPrep consists of a series of pills taken with the clear liquid. MoviPrep is a tolerable, lowvolume liquid bowel prep with the effectiveness of highvolume prep. VISICOL, the precursor to OsmoPrep, this colonoscopy preparation also features a regimen of tablets taken with any clear liquid. AnusolHC and PROCTOCORT provide soothing relief from anal itching, burning, and inflammation. AZASAN prevents rejection of kidney transplant and provides therapy for the management of severe active rheumatoid arthritis. Diuril treats high blood pressure and is an adjunctive therapy in edema associated with congestive heart failure, cirrhosis of the liver, corticosteroid and estrogen therapy, and kidney disease. The Company mainly sells its products to pharmaceutical wholesalers. The Company uses third party manufacturers to produce its products. The research, testing, manufacture, marketing and distribution of drug products are extensively regulated by governmental authorities in the United States and other countries.
» More Articles for SLXP

Headlines

Articles On GuruFocus.com
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Salix Pharmaceu Dec 12 2014 
Pharmaceutical Giant Merck Buys Cubist Pharma Dec 09 2014 
Bill Ackman and Valeant Could Sweeten Allergan Deal By $15 A Share Oct 10 2014 
Steven Cohen Has a Track Record of Impressive Returns Jul 31 2014 
Joel Greenblatt's Gotham Capital Top 5 New Stocks May 16 2014 
Weekly CFO Sells Highlight: FII, SLXP, CCK, VCI, WDC, STMP Dec 31 2012 
Weekly Guru Bargains Highlights: HMSY, FB, TSU, SLXP, ANR Oct 29 2012 
Value Shop Nuveen Investments Reports Second Quarter Portfolio Aug 19 2011 
Hedge Fund Giant John Paulson Reports Q2 Portfolio Aug 15 2011 
Salix Pharmaceuticals Ltd. (SLXP) President & CEO Carolyn J Logan sells 14,000 Shares Sep 23 2010 


Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK